


**FIG. 1**

TARGET CELLS: OVARIAN CANCER LINE PEO-1 (ENDOGENOUS MUC16+)




FIG. 2A

3/24




FIG. 2B




FIG. 2C

4/24







FIG. 2D

**FIG. 2E**

TARGET CELLS: OVARIAN CANCER LINE PEO-1 (ENDOGENOUS MUC16+)

**FIG. 2F**

6/24




FIG. 2G





FIG. 2H

7/24



●	MUC16xCD28		EC50
○	MUC16xCD3	MUC16xCD28	6.789E-010
▼	CD3-BINDING CONTROL	MUC16xCD3	1.843E-009
		CD3-BINDING CONTROL	~2.274E-009

FIG. 2I

8/24




FIG. 3A





FIG. 3B



9/24




FIG. 3C

10/24




FIG. 4A




FIG. 4B

11/24




FIG. 5

12/24







FIG. 6A

**FIG. 6B**

**FIG. 6C****FIG. 6D**




FIG. 7




FIG. 8A

17/24




FIG. 8B







FIG. 8C

**FIG. 9A****FIG. 9B**

**FIG. 10**




FIG. 11A











FIG. 11B



DONOR 555014

DONOR 555109

DONOR 555131



- ▲ bs24963D + REGN4018
- ▼ bs24963D + NON-TAAxCD3
- △ NON-TAAxCD28 + REGN4018
- ▽ NON-TAAxCD3 + NON-TAAxCD28

FIG. 13




FIG. 14




FIG. 15